ストックスクリーナーアプリを入手
2.30
4.17%
-0.10
アフターアワーズ：
2.20
-0.10
-4.35%
前日終値:
$2.40
開ける：
$2.6
24時間の取引高:
43,146
Relative Volume:
0.08
時価総額：
$14.29M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-19.01%
1か月 パフォーマンス:
-30.51%
6か月 パフォーマンス:
-60.88%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$2.26
$2.6918
1週間の範囲:
$2.26
$2.87
52週間の値動き範囲:
$2.2416
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
TRAW を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.30 | 14.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-03-01 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-05-18 | 開始されました | Guggenheim | Buy |
| 2018-03-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-09 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-27 | 開始されました | Laidlaw | Buy |
| 2015-07-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Traws Pharma Inc (TRAW) 最新ニュース
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost By Investing.com - Investing.com South Africa
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost - Investing.com
Traws Pharma Reports 2024 Financial Results and CEO Change - TipRanks
Traws Pharma CEO Werner Cautreels to retire - MSN
Traws Pharma Reports Full Year 2024 Results and Business Highlights - Yahoo Finance
Traws Pharma (TRAW) Expected to Announce Quarterly Earnings on Monday - Defense World
Traws Pharma Announces CEO Transition as Werner Cautreels Retires - MSN
Traws Pharma announces CEO retirement and interim successor By Investing.com - Investing.com South Africa
Traws Pharma announces CEO retirement and interim successor - Investing.com India
Traws Pharma CEO Werner Cautreels Retires, Chair Iain Duke Succeeds on Interim Basis - MarketScreener
Traws Pharma Announces Management Updates - GlobeNewswire
Leadership Shift at Traws Pharma: Chairman Steps Up as CEO Exits, Key Antiviral Programs Continue - Stock Titan
Traws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19 - MyChesCo
Traws Pharma Reports Promising Preclinical Results for Bird Flu Treatment - MSN
Traws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 Treatment - MSN
Traws Pharma to Host Investor Event on Bird Flu and COVID - GlobeNewswire
Former CDC Director Unveils Game-Changing Bird Flu and COVID Treatments at Traws Pharma Event - Stock Titan
Traws Pharma’s ratutrelvir shows promise in COVID-19 treatment By Investing.com - Investing.com South Africa
Traws Pharma’s ratutrelvir shows promise in COVID-19 treatment - Investing.com
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR - GlobeNewswire
Breakthrough: Next-Gen COVID Drug Defeats 18 Variants Without Ritonavir Boost - Stock Titan
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates - GlobeNewswire
Breakthrough: New Bird Flu Drug Achieves Remarkable 99.9% Viral Reduction in Latest Primate Tests - Stock Titan
Traws Pharma Unveils Promising Bird Flu Treatment Data - MyChesCo
Traws Pharma touts bird flu drug efficacy at ICAR By Investing.com - Investing.com South Africa
Traws Pharma touts bird flu drug efficacy at ICAR - Investing.com
Traws Pharma Presents Positive Data For TXM As Bird Flu Treatment At ICAR -March 21, 2025 at 07:03 am EDT - Marketscreener.com
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - GlobeNewswire
Breakthrough: Revolutionary Bird Flu Drug Achieves Perfect Survival Rate in Latest Trial Data - StockTitan
Traws Pharma Enters $50 Million ATM Agreement With Citizens JMP Securities -March 10, 2025 at 05:35 pm EDT - Marketscreener.com
Traws Pharma Announces Promising Preclinical Results for Bird Flu Treatment - MSN
PA-based biopharma company reports positive results testing efficacy of bird flu antiviral - Pennsylvania Business Report
TRAW stock touches 52-week low at $2.14 amid sharp annual decline - Investing.com
Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update - Defense World
Traws Pharma reports promising bird flu treatment results By Investing.com - Investing.com Canada
Traws Pharma reports promising bird flu treatment results - Investing.com India
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil - GlobeNewswire
Can Traws Pharma's Single-Dose Treatment Combat the Growing Bird Flu Threat? - StockTitan
Traws Pharma Reports Positive Results From Accepted Bird Flu Model For Anti-Viral Candidate, Tivoxavir Marboxil - Marketscreener.com
Traws Pharma regains Nasdaq compliance - MSN
Soleno Therapeutics Reports 2024 Financial Results and Strategic Progress - MSN
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule - GlobeNewswire
Traws Pharma Regains Nasdaq Compliance, Strengthening Position for 2025 - MSN
Traws Pharma Regains Nasdaq Compliance, Strengthens Position For Antiviral Development - Nasdaq
Traws Pharma meets Nasdaq equity requirement By Investing.com - Investing.com Canada
Traws Pharma Regains Nasdaq Compliance with $20M Financing - TipRanks
Traws Pharma meets Nasdaq equity requirement - Investing.com
Traws Pharma Inc (TRAW) 財務データ
Traws Pharma Inc (TRAW) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):